April 2007 in “Nature Clinical Practice Urology” Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.
February 2003 in “European Urology Supplements” Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
April 2012 in “The Journal of Urology” PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
March 2015 in “The Journal of Urology” Finasteride reduces PSA levels by around 40-50% in BPH patients.
September 2017 in “ics.org” Higher PSA levels can indicate prostate cancer, but there's overlap with non-cancerous conditions.
November 2005 in “The Journal of Urology” September 2023 in “Journal of the American Academy of Dermatology” Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
46 citations
,
January 2005 in “PubMed” Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
33 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
22 citations
,
January 2017 in “Skin appendage disorders” The conclusion is that primary scarring alopecia is a complex condition that requires early and accurate diagnosis for effective treatment.
20 citations
,
December 2015 in “Der Urologe” Combining medications is more effective for treating benign prostatic syndrome symptoms.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
14 citations
,
January 2003 in “Actas Urológicas Españolas” Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
11 citations
,
April 2020 in “Andrology” Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.
11 citations
,
September 2006 in “European Urology Supplements” Combination therapy for BPH is cost-effective, especially for men with larger prostates.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
9 citations
,
September 2010 in “Dermatologic Therapy” Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
6 citations
,
June 2009 in “Journal of Clinical Oncology” 5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
6 citations
,
January 2003 in “PubMed” Finasteride reduces prostate size and symptoms with few side effects.
5 citations
,
June 2015 in “Chinese journal of natural medicines/Zhongguo tianran yaowu/Chinese Journal of Natural Medicines” Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.
5 citations
,
September 2012 in “The Journal of Urology” Early hair loss may indicate future prostate issues.
3 citations
,
January 2015 in “DOAJ (DOAJ: Directory of Open Access Journals)” There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.
3 citations
,
April 2003 in “BJUI” Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.
2 citations
,
February 2006 in “Mayo Clinic Proceedings” Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.